Tyra Biosciences Inc TYRA

Healthcare Biotechnology

Tyra Biosciences, Inc. is a clinical-stage biotechnology company. It is focused on developing precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. Its in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations to cause acquired resistance to existing therapies. Its initial focus is on applying its accelerated small molecule drug discovery engine to develop therapies in targeted oncology and genetically defined conditions. Its lead product candidate, TYRA-300, is an investigational, oral, FGFR3-selective inhibitor being evaluated in an international, multi-center, open label Phase 1 clinical study, SURF301. Its second oncology product candidate, TYRA-200, is an investigational, oral, FGFR1/2/3 inhibitor with potency against activating FGFR2 gene alterations, and clinically important molecular brake and gatekeeper resistance mutations.

NDAQ:TYRA - Post by User

Tyra Biosciences Inc

<< Previous

Bullboard Posts

Post by whytestockson Feb 02, 2024 3:45pm

39 Views

Post# 35860266

US Companies Moving the Markets, Evening edition <br>Fri, Fe

NEWS: $TYRA US Companies Moving the Markets, Evening edition <br>Fri, Feb 02, 2024 as of 4:00 pm ETA look at the top 10 most actives in the United States PROSHARES TRUST (SQQQ) fell 5.5% to $11.665 on volume of 166,461,596 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) fell 4.1% to $5.075 on volume of 129,958,072 shares Remark Holdings Inc. (MARK) rose 16.2% to $0.593899 on ...TYRA - US Companies Moving the Markets, Evening edition <br>Fri, Feb 02, 2024 as of 4:00 pm ET

<< Previous

Bullboard Posts

Digihost and Nano Nuclear team up to advance carbon-free energy transition